Life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO) announced on Monday that it plans to unveil its expanded biopharma services and innovations at CPHI Milan 2024 from 8-10 October. The company will highlight its latest offerings aimed at streamlining the molecule-to-medicine process and advancing drug development.

Thermo Fisher's Accelerator Drug Development, its 360° CDMO and CRO services, are designed to support pharmaceutical and biotech companies from pre-clinical stages through to commercialisation, covering small molecules, biologics, and cell and gene therapies.

The company has enhanced its capabilities by expanding oral drug development facilities in Cincinnati and Bend, focusing on research, manufacturing and testing. Global clinical trial logistics have also been strengthened with investments in Argentina, Switzerland and a new ultra-cold facility in the Netherlands. Additionally, Thermo Fisher opened an Innovation Lab in Pennsylvania, fostering collaboration and addressing challenges in clinical trials.

A strategic partnership with Stevanato Group aims to streamline production of Vertiva on-body delivery systems, enhancing patient-centric treatments. In Monza, Italy, advanced training centers using AR and VR technologies are being utilised to drive innovation in steriles manufacturing.

Thermo Fisher's PPD clinical research division is expanding with a new bioanalytical lab in Sweden, advancing global health innovation. In collaboration with DHL Express, the company is also investing in sustainable logistics for clinical trials, targeting an 80% reduction in greenhouse gas emissions.

Thermo Fisher Scientific reported annual revenue exceeding USD40bn and continues to lead in providing pharmaceutical and life science solutions.